drug_type
RELEVANT_DRUG
intervention_type
cellular therapy (CAR T cells)
drug_description
Engineered autologous T cells expressing a chimeric antigen receptor targeting BCMA (TNFRSF17) on malignant plasma cells; administered twice around ASCT to mediate targeted cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor targeting BCMA (TNFRSF17) on malignant plasma cells; antigen binding triggers CAR signaling (CD3ζ ± costimulatory domains), activating cytotoxicity, cytokine release, and proliferation to eliminate BCMA-positive cells.
drug_name
Autologous anti-BCMA CAR-T cells
nct_id_drug_ref
NCT05870917